NeoDynamics appoints Matthew Colpoys, to lead US operations
NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced the appointment of current board member Matt Colpoys as head of the company’s US subsidiary. Colpoys will remain on the board and will report to CEO Anna Eriksrud.
“Matt is an experienced executive with an extensive background in new product launches, commercialization and corporate finance. He has also guided international companies in US launch efforts in the past – a perfect fit for NeoDynamics as we move quickly to introduce our innovative pulse biopsy system NeoNavia to the US market,” said Anna Eriksrud CEO of NeoDynamics. “Matt completely understands our goals in this critical market, and has shown himself to be a valuable asset in efforts to finance and prepare for our US commercialization.”
Mr. Colpoys has over 35 years’ experience in the biopharmaceutical/medtech industry. Most recently he founded and led Tactiva Therapeutics, Inc., an Immuno-Oncology start up, through their $35M Series A fund raise. He was a key member of the early commercial and management teams at Genentech (Sold to Roche), Pharmacia (Sold to Pfizer), Neurex (Sold to Elan) and Insmed. At these companies his integral participation resulted in a number of successful commercial product launches, two of which resulted in products currently selling in excess of $300M (US). As President of Galileo Consulting, a global biopharmaceutical advisory and consulting practice, he has assisted a wide range of companies in their business development, strategic planning, fundraising and M&A activities.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
Aaron Wong, CFO NeoDynamics AB, phone +46735 972 011 or e-mail aaron.wong@neodynamics.com
About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and will soon launch in the USA. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.